All > Lymphoma

Loncastuximab Tesirine for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Hodgkin's Lymphoma+1 MoreLoncastuximab Tesirine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a new drug, loncastuximab tesirine, can help control large B-cell lymphoma that has returned or is resistant to CAR T-cell therapy. The safety and possible effects of the new drug will also be studied.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Autologous CD30.CAR-T
1
Loncastuximab Tesirine
1
LMY-920 dose escalation

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion and or average of 1 year

Year 1
Rate of conversion to complete response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Autologous CD30.CAR-T
1
Loncastuximab Tesirine
1
LMY-920 dose escalation

Trial Design

1 Treatment Group

Loncastuximab Tesirine
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Loncastuximab Tesirine · No Placebo Group · Phase 2

Loncastuximab Tesirine
Drug
Experimental Group · 1 Intervention: Loncastuximab Tesirine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Loncastuximab Tesirine
2021
Completed Phase 2
~10

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion and or average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,802 Previous Clinical Trials
1,788,873 Total Patients Enrolled
Paolo Strati, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
52 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have no evidence of disease or have disease that is in a stable or progressive state.
You have achieved a complete response according to the 2014 response criteria.
You must have received CAR T-cell therapy at least 30 days before the date of the assessment.
CD19 expression is not required for enrolment in this trial.
You have a neutrophil count of ≥ 1.
Platelet count of ≥ 50×109/L without transfusion for 7 days prior to screening assessment.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top